Haleon not a party to U.S. litigation focused on Zantac – spokesperson
2022.08.11 14:46
2/2
FILE PHOTO: The company logo for Haleon and the trading info is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., July 20, 2022. REUTERS/Brendan McDermid
2/2
LONDON (Reuters) – Haleon – GSK’s recently spun off consumer health unit – is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.
“We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare,” the spokesperson said in response to queries about sharp declines in Haleon shares.
Given over-the-counter Zantac has been sold by several companies over time, that “may make third parties liable ahead of any Haleon exposure,” the spokesperson added.
